Condition
Nasopharyngeal Cancers
Total Trials
4
Recruiting
1
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 90/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
50.0%
-36.6% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (1)
P 3 (1)
Trial Status
Recruiting1
Unknown1
Terminated1
Completed1
Trial Success Rate
50.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07038343Phase 1Recruiting
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
NCT00828386Phase 3TerminatedPrimary
Induction Chemotherapy and Chemoradiotherapy in Nasopharyngeal Cancers
NCT02149641CompletedPrimary
Parotid-sparing IMRT for Nasopharyngeal Cancer
NCT01806272Phase 2UnknownPrimary
Recombinant Human Granulocyte Macrophage Colony Stimulating Factor(rhGM-CSF) Treating Oral Mucositis
Showing all 4 trials